Nicotine

Cotinine Testing (Primary Method)

Cotinine is the primary metabolite of nicotine and is the standard biomarker used to detect nicotine use. It has a much longer half-life than nicotine itself (16-19 hours vs. 1-2 hours), making it far more practical for detection purposes.

Detection windows by sample type:

Urine cotinine testing is the most commonly used method due to its non-invasive nature and adequate detection window. Quantitative results can help distinguish between active tobacco/nicotine use, passive exposure, and cessation.

Anabasine and Anatabine Testing

Anabasine is a minor tobacco alkaloid that is present in tobacco products but absent from pharmaceutical nicotine replacement therapy (NRT) products. Testing for anabasine allows clinicians and insurers todistinguish between active tobacco use and NRT use (patches, gum, lozenges).

• This distinction matters for insurance underwriting — many life and health insurance companies charge significantly higher premiums for tobacco users (sometimes 50-200% more)
• A positive cotinine test combined with a negative anabasine test suggests NRT use, not tobacco/smoking
• Anatabine serves a similar purpose as a tobacco-specific marker

Insurance and Employment Screening

Nicotine/cotinine testing is standard in several contexts:

• Life insurance applications — virtually all major insurers test for cotinine. Tobacco users typically pay 2-3x higher premiums. Deceptively reporting non-smoker status and testing positive is grounds for policy denial or rescission
• Health insurance — under the Affordable Care Act (US), insurers can charge tobacco users up to 50% more in premiums
• Employment screening — some employers (particularly hospitals and healthcare systems) have nicotine-free hiring policies and test applicants. This is legal in most US states, though a handful of states have "smoker protection" laws
• Pre-surgical screening — many surgeons require nicotine cessation before elective procedures (especially plastic surgery and orthopedic surgery) because nicotine impairs wound healing and increases complication rates

Quantitative vs. Qualitative Tests

• Qualitative tests simply report positive or negative based on a cutoff threshold. Used for most screening purposes
• Quantitative tests report the actual concentration of cotinine, which can help assess the level of use, distinguish heavy use from light use, and monitor cessation progress over time

False Positives and Secondhand Smoke

Significant secondhand smoke exposure can cause cotinine levels above the limit of detection, but typically below standard screening cutoffs. At the standard 200 ng/mL cutoff for urine cotinine, false positives from passive exposure are uncommon. However, at lower cutoffs (50-100 ng/mL), individuals with heavy environmental exposure (living with a smoker, working in a smoking-permitted venue) may test positive. Hair testing is more susceptible to external contamination from environmental tobacco smoke. Some testing protocols account for this by using higher cutoffs or confirmatory testing.

The Hierarchy of Harm: Delivery Method Is Everything

The single most important harm reduction principle for nicotine is understanding that nicotine itself, while addictive, is not the primary cause of smoking-related disease. The overwhelming majority of harm comes from the combustion of tobacco -- the tar, carbon monoxide, and thousands of toxic and carcinogenic byproducts generated when plant matter burns. The hierarchy of harm, from most to least dangerous, is roughly: combustible cigarettes > cigars and pipes > heated tobacco products > vaping and e-cigarettes > nicotine replacement therapy (patches, gum, lozenges) > abstinence. Any step down this ladder represents a meaningful reduction in health risk.

For Current Smokers: Switching to Reduced-Harm Products

Switching to a regulated vaping device with known e-liquid composition eliminates the vast majority of combustion-related toxicants. While vaping is not risk-free -- long-term respiratory effects are still being studied -- public health bodies including the UK Royal College of Physicians have estimated it to be at least 95% less harmful than smoking. The key caveats: use regulated products with known ingredients, avoid black-market or THC-containing cartridges (implicated in the EVALI lung injury outbreak), and do not dual-use (smoking and vaping simultaneously provides minimal benefit over smoking alone).

Nicotine Replacement Therapy

NRT represents the lowest-risk form of nicotine delivery and is available over the counter in most countries. Patches provide steady-state nicotine levels that reduce baseline cravings. Gum and lozenges offer faster-acting relief for acute cravings and can be used in combination with patches for better efficacy. The standard patch step-down protocol (21 mg to 14 mg to 7 mg over 8-12 weeks) is well-studied. Important detail: nicotine gum should be "parked" between the cheek and gum rather than chewed like regular gum -- swallowing nicotine causes nausea and reduces absorption through the buccal mucosa.

Quitting Entirely

Gradual tapering is strongly preferred over abrupt cessation. While nicotine withdrawal is not medically dangerous (unlike alcohol or benzodiazepine withdrawal), it produces significant irritability, anxiety, difficulty concentrating, increased appetite, and sleep disturbance that peak around days 3-5 and can persist for 2-4 weeks. Pharmacological support dramatically improves success rates: varenicline (Chantix/Champix) is the most effective single agent, roughly tripling quit rates compared to placebo. Bupropion (Wellbutrin/Zyban) is also effective. Combining NRT with behavioral counseling produces the best overall outcomes. Resources include national quitlines, the SmokeFree app, and communities like r/stopsmoking.

Dangerous Combinations

Avoid combining nicotine with other stimulants (high-dose caffeine, amphetamines, cocaine) -- cardiovascular strain compounds, with elevated heart rate, blood pressure spikes, and increased risk of cardiac events, particularly in those with pre-existing conditions. Nicotine is a mild diuretic; stay hydrated. Pay attention to oral health if using smokeless tobacco, nicotine pouches, gum, or vaping -- regular dental checkups catch early signs of gum disease or mucosal lesions.

Recognizing Dependency

If you need nicotine within 30 minutes of waking, if you feel anxious or irritable when you cannot use it, or if you have tried to quit multiple times without success, you are experiencing nicotine dependency. This is not a moral failing -- nicotine is one of the most addictive substances known to pharmacology. It does mean that willpower alone is unlikely to succeed, and pharmacological support plus behavioral counseling produces substantially better outcomes than either approach alone.

Acute Toxicity and Lethal Dose

Nicotine is considerably more acutely toxic than most other common stimulants. The traditional estimate of 40-60 mg as the lethal adult dose (approximately 0.5-1.0 mg/kg) has been cited since the 19th century but is likely a significant underestimate. A 2014 review by Bernd Mayer in Archives of Toxicology re-examined the original sources and concluded that the actual lethal dose for adults is more likely in the range of 500-1,000 mg (6.5-13 mg/kg) of ingested nicotine, based on documented cases of survival after much higher doses. However, the traditional 40-60 mg figure remains relevant as a dose that can cause severe poisoning requiring medical intervention. Nicotine readily passes through the skin into the bloodstream on contact, so safety precautions are essential when handling it in pure or concentrated form.

E-Liquid and Child Safety

Flavored e-liquids intended for electronic cigarettes represent the most significant contemporary nicotine poisoning risk. A 30 mL bottle of 36 mg/mL e-liquid contains 1,080 mg of nicotine. These products are often brightly colored and flavored (candy, fruit, dessert), making them attractive to young children. As little as 1 mg of nicotine can cause symptoms in a small child. Calls to US poison control centers regarding e-liquid exposure in children increased dramatically with the rise of vaping. The Child Nicotine Poisoning Prevention Act of 2015 requires child-resistant packaging, but enforcement is imperfect and many imported products do not comply. Always store e-liquid in locked, childproof containers away from children and pets.

Chronic Toxicity: Nicotine vs. Combustion

The critical distinction in nicotine toxicity is between the molecule itself and its delivery mechanism. Nicotine's chronic effects -- including cardiovascular strain (vasoconstriction, elevated heart rate, elevated blood pressure), impaired wound healing, and potential effects on fetal neurodevelopment -- are real but modest compared to the devastating toxicity of combustible tobacco. Smoking-related disease (lung cancer, COPD, cardiovascular disease, stroke) is overwhelmingly caused by the products of combustion, not nicotine. This distinction is the foundation of tobacco harm reduction strategies.

Pregnancy

Nicotine has been associated with increased frequency of congenital abnormalities, low birth weight, preterm birth, and has been correlated with increased incidence of attention deficit hyperactivity disorder in children. Pregnant individuals should avoid all nicotine products where possible, though NRT may be considered if the alternative is continued smoking (the harm from combustion exceeds the harm from nicotine alone).

Tolerance and Receptor Dynamics

Chronic nicotine use produces rapid tolerance through nAChR desensitization, followed by compensatory receptor upregulation. In some individuals, measurable tolerance to the dizziness and nausea of nicotine develops after as few as one or two cigarettes. The brain clears nicotine rapidly (half-life approximately 90 minutes in the brain, 1-2 hours systemically), which means withdrawal symptoms begin within hours. Following complete cessation, upregulated receptors may take several months to return to baseline density -- explaining why relapse risk remains elevated long after acute withdrawal has resolved.

Dangerous Interactions

• Other stimulants (caffeine, amphetamines, cocaine) -- additive cardiovascular strain, elevated heart rate and blood pressure, increased cardiac event risk
• Cardiovascular medications -- nicotine's vasoconstrictive effects can oppose antihypertensive medications
• Oral contraceptives -- the combination of nicotine (particularly via smoking) with hormonal contraceptives significantly increases risk of blood clots, stroke, and myocardial infarction, especially in women over 35
• Psychiatric medications -- smoking (not nicotine per se, but the CYP1A2 induction from combustion) accelerates metabolism of many psychiatric drugs including clozapine, olanzapine, and some antidepressants; quitting smoking can cause plasma levels to rise, potentially requiring dose adjustment

Global Legal Status

Nicotine in the form of tobacco products is legal in virtually every country worldwide, subject to age restrictions and various regulatory frameworks. It is one of the most widely used psychoactive substances globally, with approximately 1.3 billion tobacco users worldwide as of 2023 (WHO estimate).

Age Restrictions

• 18 years — most countries worldwide, including the United Kingdom, most of the European Union, Australia, Canada (some provinces), China, Japan, Brazil
• 19 years — South Korea, some Canadian provinces (Ontario, Nova Scotia, etc.)
• 20 years — Japan (raised from 18 to 20 for heated tobacco products)
• 21 years — United States (federal Tobacco 21 law signed December 2019, raising from 18), Sri Lanka, Palau, Honduras, Kuwait, several other countries
• No minimum age — a small number of countries have no legal age restriction for tobacco purchase

Tobacco Advertising and Marketing Bans

Advertising restrictions have been one of the most effective tobacco control measures:

• Comprehensive advertising bans — Norway (1975, one of the first), Finland, France, Australia, UK, Russia, India, Thailand, and most EU countries under the 2003 Tobacco Advertising Directive
• Partial bans — the US prohibits TV and radio advertising (since 1971) but allows print advertising with restrictions, point-of-sale marketing, and sponsorships (with limitations since the 1998 Master Settlement Agreement)
• Display bans — several countries (UK, Australia, Ireland, Norway) prohibit visible displays of tobacco products in retail settings, requiring them to be kept behind opaque shutters

Plain and Standardized Packaging

• Australia pioneered plain packaging in 2012, removing all brand colors, logos, and trademarks. Packs are a uniform drab dark brown color with large graphic health warnings covering 75-82.5% of the surface
• Countries that followed: France, UK, Ireland, Norway, New Zealand, Hungary, Slovenia, Turkey, Saudi Arabia, Thailand, Uruguay, Canada, Belgium, Netherlands, Singapore, and others — over 20 countries have now adopted or announced plain packaging
• Legal challenges by tobacco companies (including a high-profile WTO dispute brought by several countries against Australia) have largely failed

Indoor Smoking Bans

Most developed countries have implemented comprehensive smoke-free laws covering workplaces, restaurants, bars, and public spaces. Notable examples include Ireland (2004, first country with a nationwide workplace ban), the UK (2007), and most US states (though enforcement varies). Some countries have extended bans to outdoor areas including parks, beaches, and sidewalk cafes.

E-Cigarette and Vaping Regulations

The regulatory landscape for e-cigarettes and vaping products is fragmented and rapidly evolving:

• Banned or effectively banned — India (complete ban since 2019), Brazil, Thailand, Singapore, Australia (prescription-only since 2021), Argentina, Mexico, several other countries
• Regulated as tobacco products — European Union (under the Tobacco Products Directive — max 20 mg/mL nicotine, max 2 mL tank capacity for refillable devices, max 10 mL for refill bottles), United Kingdom (similar to EU regulations)
• Regulated by FDA — United States. The FDA gained regulatory authority over e-cigarettes in 2016. All products require premarket authorization (PMTA). As of 2024, only a small number of products have received marketing authorization; millions of unauthorized products remain on the market in a complex enforcement landscape
• Minimal regulation — some countries have few specific e-cigarette laws

Flavor Bans

• The US banned most flavored cartridge-based e-cigarettes in 2020 (excluding tobacco and menthol flavors), though flavored disposable vapes exploited a loophole
• The EU banned characterizing flavors in cigarettes (including menthol) in 2020
• The US banned menthol cigarettes (FDA final rule issued in 2024, with implementation ongoing)
• Several US states and cities have enacted broader flavor bans on all tobacco and vaping products
• Canada, the Netherlands, Finland, and Denmark have implemented or announced restrictions on flavored vaping products

Nicotine Pouches and Heated Tobacco

• Nicotine pouches (Zyn, Velo, etc.) occupy a regulatory gray area in many jurisdictions. They are tobacco-free but contain nicotine. In the EU, they are not covered by the Tobacco Products Directive. Some countries regulate them as food products, some as novel nicotine products, and some have not yet classified them
• Heated tobacco products (IQOS, Glo, Ploom) are regulated as tobacco products in most jurisdictions. The FDA authorized IQOS as a "modified risk tobacco product" in the US in 2020

Taxation

Tobacco products are subject to excise taxes in virtually all countries, often representing 50-80% of the retail price. The WHO recommends that tax should constitute at least 75% of the retail price. The highest cigarette prices (driven by tax) are found in Australia, New Zealand, Norway, the UK, and Ireland, where a pack of 20 cigarettes can cost $25-40 USD equivalent.